docetaxel-loaded nanopharmaceutical (CRLX301) / Ellipses Pharma, Lumos Pharma - LARVOL DELTA

Multifunctionality of cyclodextrin-based polymeric nanoparticulate delivery systems for chemotherapeutics, combination therapy, and theranostics. (PubMed, Int J Pharm) - "Further, in light of recent studies, the article majorly focuses on conveying how promoting CD to a polymeric and nanoscale elevates the multifunctional advantages against cancer that can be successfully applied in combination therapy and theranostics. Moreover, CD-based delivery systems including CALAA-01, CRLX101, and CRLX301, have demonstrated improved tumor targeting, reduced side effects, and prolonged drug release in preclinical studies and clinical trials."

Combination therapy • Journal • Review • Oncology

GI Cancer ESMO 2023 Highlights : Episode 3: GASTFOX: Evaluate FOLFOX With or Without Docetaxel (TFOX) as First-Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma (Targeted Oncology) - "Rachna Shroff, MD, details key data from the phase III GASTFOX study comparing FOLFOX to docetaxel (TFOX) in the first line treatment of advanced gastric cancer."

Video

First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. (PubMed, Invest New Drugs) - P1/2 | "CRLX301 exhibited some PK advantages over docetaxel including higher retention of drug in plasma, slower clearance and controlled slow release of docetaxel from the carrier. Conclusions In this heavily pretreated patient population, the safety profile was acceptable for CRLX301 therapy. There was some evidence of preliminary tumor efficacy, but further work is necessary to find the optimal dose and schedule of this formulation.Clinicaltrials.gov trial registration number: NCT02380677 (Date of registration: March 2, 2015)."

Clinical • Journal • P1/2 data • Breast Cancer • Fatigue • Hematological Disorders • Neutropenia • Oncology • Pain • Solid Tumor

New Treatment Indications Boost Survival in Metastatic Hormone-Sensitive Prostate Cancer (OncLive) - '"In addition to data from the CHAARTED, STAMPEDE, and LATITUDE trials, which [collectively] showed that 6 cycles of docetaxel and ongoing treatment with abiraterone and prednisone results in a significant improvement in survival, we now have data showing that enzalutamide and apalutamide improve survival as well,' said Oh..."

Interview

[VIRTUAL] Analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRLX301, a nanoparticle of docetaxel (AACR-II 2020) - "MT-DTE can be detected and analyzed quantitatively in CTCs by tubulin immunofluorescence. The clinical utility of the 1-week CTC DTE should be tested and validated in future clinical trials involving nanoparticle formulations of taxanes or taxanes in general."

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CTCs

Study: AI may help predict responses to systemic therapies in non-small cell lung cancer (Pharmacy Times) - "A study published in Clinical Cancer Research has shown that using standard-of-care computed tomography (CT) scans in patients with advanced non-small cell lung cancer (NSCLC) can predict tumor sensitivity to 3 systematic cancer therapies by using artificial intelligence (AI)....The nivolumab, docetaxel, and gefitinib prediction models achieved an AUC of 0.77, 0.67, and 0.82 in the validation cohorts."

Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2; N=42; Terminated; Sponsor: NewLink Genetics Corporation; Active, not recruiting ➔ Terminated; Company decision

Clinical • Trial termination